Jared Lopes
About Jared Lopes
Jared Lopes is the Director of Oncology Research at Alkermes in Waltham, Massachusetts, specializing in cancer immunotherapy and inflammation.
Company
Jared Lopes is currently working at Alkermes in Waltham, Massachusetts, United States. Alkermes is a biopharmaceutical company focused on developing innovative medicines for the treatment of chronic diseases such as cancer, neurological disorders, and addiction. Jared's role within the company is pivotal in advancing oncology research.
Title
Jared Lopes holds the title of Director, Oncology Research at Alkermes. He assumed this position on July 1, 2021, and is responsible for leading and overseeing research initiatives related to cancer treatment and immunotherapy.
Education and Expertise
Jared Lopes has a robust educational background beginning with a B.Sc. in Cellular Biology and Genetics from The University of British Columbia, attained from 1997 to 2001. He further pursued a Ph.D. in Immunology at the University of Washington - School of Medicine, which he completed from 2002 to 2007. His expertise lies in immunological research, employing advanced biochemical, molecular, and cellular techniques. His specialization is particularly focused on cancer immunotherapy and inflammation.
Professional Background
Before his current role, Jared Lopes amassed significant experience at Alkermes. His roles included Principal Scientist (2018-2021), Senior Scientist I (2015-2018), and Scientist III, Discovery Research and Biologics (2010-2015). Additionally, Jared has worked as a Research Fellow at Harvard Medical School (2009-2010), as a Post-doc at Joslin Diabetes Center (2008-2009), and as a Grad Student at the University of Washington (2002-2007). His career is marked by over a decade of contribution to preclinical development of novel protein therapeutics targeting cancer and inflammation.
Achievements in Immunotherapy Research
Over the span of more than 10 years, Jared Lopes has significantly supported the preclinical development of novel protein therapeutics. His work primarily targets immune cells to promote anti-tumor immune responses. This specialized focus in cancer immunotherapy has contributed to advancing research and development efforts at companies such as Alkermes, where he leverages his expertise in biochemical, molecular, and cellular techniques.